You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)擬參與投資設立新藥創新基金
格隆匯 10-16 18:38

格隆匯10月16日丨復星醫藥(02196.HK)公告,2019年10月16日,上海復星醫藥(集團)股份有限公司與蘇州吳中經濟技術開發區管理委員會及蘇州市吳中金融控股集團有限公司簽訂《戰略合作框架協議》,就參與投資設立新藥創新基金等達成合作意向。

吳中經開區位於東太湖濱,是江蘇省政府批准的首批省級開發區之一,規劃面積150平方公里,户籍人口19萬,常住人口約52萬。2012年12月,吳中經開區升格為國家級經濟技術開發區,擁有吳中綜合保税區、東太湖科技金融城兩個國家級平台以及吳淞江科技產業園、蘇州(太湖)軟件產業園、生物醫藥產業園等特色功能載體,形成了以吳中太湖新城為引領的“一核一圈一廊一區”產業和城市空間佈局。2018年,吳中經開區位列商務部國家級經開區綜合發展水平考核排名第47位。

吳中金控成立於2014年6月,註冊地為蘇州市,法定代表人為李文龍。吳中金控的經營範圍為對全區銀行業金融企業、非銀行業金融企業、金融服務企業及其他行業的投資經營和管理(依法須經批准的項目,經相關部門批准後方可開展經營活動)。截至公告日,吳中金控的註冊資為人民幣11億元,其中:蘇州市吳中區國有資產監督管理局持有吳中金控100%股權,為其控股股東。

新藥創新基金擬由復星醫藥及其控股子公司發起募集設立,首期募集資金規模約人民幣10至15億元。該基金旨在充分利用集團已有的全球領先大學創投基金網絡以及前沿生物技術的豐富資源,通過基金投資+孵化落地的等模式,將海內外優質的人才與技術產品引入國內進行落地。

如次合作簽訂並履行最終協議,將有利於結合集團現有創新研發資源和吳中經開區生物醫藥產業的發展環境與政策優勢,進一步推動強化集團在大健康領域的持續創新能力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account